Merck KGaA's Erbitux drug extends survival for some
Merck KGaA and ImClone Systems Inc.'s Erbitux cancer drug extended survival in some colorectal cancer patients for more than two years, new data suggests, though the results may be due to chance.
Merck & Co. said it achieved positive results in Phase 3 trials of its experimental insomnia treatment, a key drug in the pharmaceutical giant's pipeline.